Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback